Indeed, although MSC transplantation and IDO induction have been shown to down-modulate neuroinflammation in animal models of MS [20], [26], [35], the impact and functional consequences of KP activation in patients receiving IFN-β treatment and potential stem cell transplants have not been fully explored [36], [37]. The gene discussed is IDO1; the disease is myeloid sarcoma.